Nexgel, Inc. key statistics and ratios
In fiscal 2025, Nexgel, Inc. had return on equity of -58.7%, an operating margin of -29.3%, debt equal to 15.4% of equity and a current ratio of 1.47. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.
Financial ratios
| Fiscal year | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 23.2% | −19.1% | −43.2% | 0.5% | 12.5% | 9.1% | 31.6% | 39.5% | 35.1% |
| Operating margin | −85.3% | −268.3% | −335.3% | −165.7% | −163.5% | −85.0% | −40.9% | −29.3% | −44.8% |
| Net margin | −85.3% | −268.2% | −335.9% | −277.9% | −231.7% | −77.2% | −37.8% | −26.3% | −51.3% |
| Free-cash-flow margin | — | −253.0% | −313.5% | −194.8% | −150.8% | −96.2% | −49.6% | −12.1% | −26.6% |
| Return on equity | — | — | — | −70.9% | −48.1% | −51.2% | −62.8% | −58.7% | −131.5% |
| Return on assets | −255.5% | −146.3% | −109.2% | −44.8% | −34.7% | −31.1% | −31.3% | −28.0% | −33.5% |
| Asset turnover | 2.99 | 0.55 | 0.33 | 0.16 | 0.15 | 0.40 | 0.83 | 1.07 | 0.65 |
| Current ratio | 0.89 | 0.64 | 0.27 | 4.82 | 8.74 | 1.98 | 2.07 | 1.47 | 0.43 |
| Debt to equity | 0.0% | 0.0% | 443.7% | 19.1% | 3.9% | 17.8% | 13.6% | 15.4% | 63.8% |
| Interest cover (operating income ÷ interest) | — | — | — | — | n/m | n/m | n/m | n/m | — |
| R&D as % of revenue | — | — | — | 2.0% | 17.9% | 2.5% | 0.9% | 0.0% | — |
| SG&A as % of revenue | 108.5% | 249.2% | 292.1% | 164.2% | 158.1% | 91.7% | 71.6% | 68.8% | 79.7% |
| Capital spending as % of revenue | — | 0.0% | 46.3% | 17.3% | 4.7% | 17.0% | 5.1% | 0.6% | 0.0% |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Gross margin | 39.3% | 35.3% | 42.3% | 43.6% | 42.4% | 29.3% | 40.0% | 30.1% |
| Operating margin | −26.8% | −27.7% | −27.7% | −22.1% | −24.7% | −43.4% | −36.2% | −68.0% |
| Net margin | −23.6% | −28.0% | −25.4% | −23.1% | −22.3% | −34.7% | −35.0% | −98.6% |
| Free-cash-flow margin | −41.8% | −30.5% | — | — | −27.0% | 8.6% | −19.4% | — |
| Current ratio | 1.51 | 2.07 | 1.88 | 1.74 | 1.69 | 1.47 | 1.70 | 0.43 |
| Debt to equity | 22.5% | 11.9% | 12.7% | 13.7% | 11.8% | 13.2% | 14.1% | 8.8% |
| R&D as % of revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.2% | −0.2% | — | 0.5% |
| SG&A as % of revenue | 66.1% | 63.0% | 70.0% | 65.7% | 66.8% | 72.9% | 76.2% | 97.5% |
Financial health
- Short-term assets cover short-term liabilities $6m of assets due within a year against $14m of liabilities due within a year.
- Short-term assets cover long-term liabilities $6m short-term assets against $7m of longer-dated liabilities.
- More cash than debt $2m of cash against $437,000 of debt.
- Debt below 40% of shareholders' equity Debt is 9% of equity.
- Debt burden no higher than five years ago Debt to equity moved from 2% to 9% over five years.
- A year's operating cash flow covers at least 20% of debt −$3m of operating cash flow against $437,000 of debt.
- Operating profit covers interest at least five times over No material interest expense reported.
Moat
Weak moat
How hard Nexgel's competitive advantage looks for rivals to wear away, judged from 7 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.
- Returns on capital 0 / 20
Cash operating profit has been a median -41.1% of total assets over 5 years.
- Pricing power 0 / 20
Gross margin has been a median 8.7%, moving by 18.9 percentage points (standard deviation) across 8 years.
- Durability 10 / 20
Operating margin has been a median -120.3%; its worst year was -222.4%.
- Cash conversion 0 / 20
Free cash flow was positive in 0 of 7 years, at a median -129.9% of revenue.
AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (12 before it).
Compare with peers
- Sintx Technologies, Inc. statistics
- Orasure Technologies Inc statistics
- Mimedx Group, Inc. statistics
- Organogenesis Holdings Inc. statistics
- UFP Technologies Inc statistics
Head to head: NXGL vs SINTNXGL vs OSURMDXG vs NXGL
More: Health Care Supplies stocks compared, Health Care sector, rankings of US companies